Maxim Group Believes Galmed Pharmaceuticals (NASDAQ: GLMD) Still Has Room to Grow

By Ryan Adsit

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Galmed Pharmaceuticals (NASDAQ: GLMD), with a price target of $14. The company’s shares closed on Friday at $7.79, close to its 52-week high of $8.60.

According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -11.8% and a 31.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Arbutus Biopharma Corporation, and ContraVir Pharmaceuticals Inc.

Galmed Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $13.

The company has a one year high of $8.60 and a one year low of $2.78. Currently, Galmed Pharmaceuticals has an average volume of 38.46K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs.